Abstract
Prodrug development is an important strategy for improving tumor cell targeting and the selectivity of anticancer drugs. In this study, poly(ethylene glycol) and melphalan, an anticancer drug, were linked to the backbone of hyaluronic acid via amide bonds using carbodiimide chemistry to synthesize a poly(ethylene glycol)–hyaluronic acid–melphalan prodrug. The physicochemical properties of the prodrug were characterized by Fourier transform infrared, proton nuclear magnetic resonance, ultraviolet–visible spectroscopy, and dynamic light scattering and transmission electron microscopy. The in vitro drug release profiles and the corresponding in vitro cell evaluation of the prodrug were investigated. The poly(ethylene glycol)–hyaluronic acid–melphalan prodrug was successfully synthesized and self-assembled into 116.4-nm nanoparticles. The release profiles demonstrated that controlled release of the prodrug could be achieved with a sensitive property involving both pH and enzymatic degradation. The poly(ethylene glycol)–hyaluronic acid–melphalan prodrug was more effectively transferred into the ovarian tumor cell (SKOV3) than into human ovarian fibroblast (HOF) cells. It also had a higher inhibition effect on SKOV3 and a lower inhibition effect on HOF than melphalan. This poly(ethylene glycol)–hyaluronic acid–melphalan prodrug, with its controlled release properties and selectivity, is a promising drug delivery system for cancer therapy.
Get full access to this article
View all access options for this article.
